NEWS 2020.4.9 Introduction

The world is presently facing the serious situation of the coronavirus pandemic. We all need to work together on a global basis to end this crisis.
Unfortunately, the pandemic does not decrease the incidence of other diseases.   Ideally, research and development of novel treatments for those diseases should not be constrained by the coronavirus pandemic. However, in reality, the activity in many research institutes in the world is being limited by the response to the epidemic.
Rebirthel Co., Ltd. was founded in October 2019, with the aim of developing and making available for patients a novel immune cell therapy for cancers using the technology which was developed by Professor Hiroshi Kawamoto (Institute for Frontier Life and Medical Sciences, Kyoto University).
Professor Kawamoto’s laboratory has been developing the world’s first technology to regenerate T cells from pluripotent stem cells such as iPS (induced pluripotent stem) cells or ES (embryonic stem) cells. Rebirthel’s mission is to advance this technology so as to realize cell-based therapies by using a highly universal T cell preparation that can be administered to anyone at any time as needed. The development of cancer immunotherapy is our core business, however, our technology can be expanded to target infectious diseases, autoimmune diseases, allergies, and other immune-related diseases.